Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shenzhen Haipurui Pharmaceutical Group Co., Ltd. was established in Shenzhen, China in 1998. The founder's mission is to bring good news to patients and become a leading international pharmaceutical enterprise. Continuous and unremitting efforts have enabled Haipri to establish an integrated safety supply chain, becoming the world's largest heparin sodium raw material pharmaceutical enterprise and the world's third largest enoxaparin preparation enterprise. In the EU region, formulations of the "Inhixa" and "Neoparin" brands are being commercialized on a large scale. In China, the "Prolozin" brand has become the second largest market brand after the original research brand. In addition to the aforementioned countries and regions, enoxaparin formulations are also approved for sale in dozens of other countries and regions. The entire heparin industry chain business is creating stable growth cash flow for the company. While building the cornerstone of the company's development - deeply cultivating the entire heparin industry chain, the founder of the company, as a sugar biochemistry expert, leads a global research and development team to consistently study the role of heparin and its derivatives in the life process at the molecular biology level, especially in the field of immune regulatory mechanisms, We have constructed a scientific logic for the company's innovative drug pipeline layout - research and development, exploration, and investment in first in class drugs in the field of cardiovascular and tumor diseases caused by immune imbalance, to meet significant unmet clinical needs with high mortality rates. The company currently has global asset rights for multiple innovative drugs and commercial rights for multiple clinical mid to late stage varieties in Greater China. With the gradual completion of clinical trials of innovative drug varieties globally, not only our global rights can be realized, but more importantly, the realization of commercial rights in Greater China is also within reach. In order to expand the perspective of innovative variety screening and more accurately screen new drugs, as well as accelerate the development progress of existing pipeline varieties, the company has wholly-owned acquired Cytovance, a globally leading and unique biological macromolecule CDMO company. Our biomacromolecule CDMO platform not only has a strong microbial and mammalian cell business, but also focuses on the booming gene therapy market opportunities. With its high-quality and unique technical services, it has won the trust of heavyweight customers worldwide and is becoming another rapidly growing cash flow business for the company. The complete management system and best practices for global research and development, rapid transformation, production and operation, and marketing of drugs, especially the innovative R&D pipeline, as well as the high growth CDMO business that empowers innovation, have organically combined to become the future development advantages of Hipreci. Today, Hepri will continue to practice the noble mission of "bringing gospel to global patients", which is the responsibility of all Hepri people. |
| Headquarter | Shenzhen |
| Establish Date | 4/21/1998 |
| Listed Code | 002399.SZ |
| Listed Date | 5/6/2010 |
| Chairman | Li Li. |
| CEO | Shan Yu. |
| Website | www.hepalink.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
